Epoch Investment Partners Inc. Sells 141,033 Shares of Edwards Lifesciences Co. (NYSE:EW)

Epoch Investment Partners Inc. reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 23.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 448,037 shares of the medical research company’s stock after selling 141,033 shares during the period. Epoch Investment Partners Inc. owned 0.07% of Edwards Lifesciences worth $42,814,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Martin Capital Advisors LLP grew its stake in Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after acquiring an additional 128 shares in the last quarter. Chapin Davis Inc. boosted its stake in shares of Edwards Lifesciences by 1.7% during the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after purchasing an additional 140 shares in the last quarter. Johnson Financial Group Inc. boosted its stake in shares of Edwards Lifesciences by 23.0% during the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 144 shares in the last quarter. Valley National Advisers Inc. boosted its stake in shares of Edwards Lifesciences by 6.0% during the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 152 shares in the last quarter. Finally, Choreo LLC boosted its stake in shares of Edwards Lifesciences by 4.1% during the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after purchasing an additional 153 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Bernard J. Zovighian acquired 580 shares of the business’s stock in a transaction on Monday, May 6th. The stock was bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The disclosure for this sale can be found here. Insiders sold a total of 81,099 shares of company stock valued at $7,003,553 over the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $2.67 during trading on Friday, hitting $62.37. 14,111,391 shares of the company’s stock were exchanged, compared to its average volume of 5,310,790. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.71. The business has a 50-day simple moving average of $87.98 and a 200-day simple moving average of $86.92. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $37.58 billion, a price-to-earnings ratio of 26.88, a PEG ratio of 2.31 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the company posted $0.66 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a research note on Thursday. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Citigroup raised their target price on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $82.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.